Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, is the most common form of motor neuron disease, affecting approximately 2 per 100,000 individuals, with the prevalence rates of about 1-2 per 10,000.
A definitive diagnosis of ALS is given according to the criteria of El Escorial. This process can take several months as other potential (less severe) causes of disease are considered before a final diagnosis of ALS is given.
ALS attacks the motor neurons of the brain and spinal cord. These neurons are responsible for voluntary muscle movements such as talking, walking, swallowing and breathing. Disease generally starts as a mild muscle weakness that progresses to paralysis and eventual death, usually within 2-5 years from diagnosis. Currently there is no cure and no truly effective treatment, riluzole being the only currently available FDA-approved medication for ALS.
Pathology of ALS
At autopsy, the spinal cord and affected brain regions of individuals with ALS display a number of distinguishing features. The most characteristic pathological marker of ALS is the presence of ubiquitinated inclusion bodies in affected motor neurons. A key component of these inclusions is TDP-43, with the intermediate filament protein, peripherin, also frequently observed.
Another aspect of ALS is the occurrence of cognitive decline in a proportion of individuals with the disease. This can manifest as a mild cognitive impairment in about 30% of cases, and moderate to severe impairment in about 20% of cases, with severe cases meeting the criteria for a diagnosis of Frontotemporal Dementia (FTD). Based on this, it is currently considered that ALS and FTD may be a continuum of the same underlying disorder.
Approximately 5-10% of cases are genetically inherited (Familial ALS or fALS) with the remaining 90-95% of cases occurring sporadically (Sporadic ALS or sALS), with no known cause of disease.
The most well established cause of fALS is mutations in the gene encoding copper-zinc superoxide dismutase (commonly known as SOD1), responsible for approximately 15-20% of fALS cases, which corresponds to about 1-2% of all ALS cases. SOD1 is a ubiquitously expressed enzyme that acts by removing toxic superoxide radicals generated via normal biological processes, and that can cause harm to the cell.
Over 100 different mutations have been identified in the SOD1 gene. It remains unclear how these mutations cause the disease as in most cases normal SOD1 enzymatic activity is not affected. Therefore, disease is not caused by an inability of SOD1 to remove toxic superoxide radicals. Instead the mutations appear to impart a gain of toxic function to the SOD1 protein. The nature of this toxicity remains unknown but may be linked to the increased propensity for mutant forms of SOD1 to misfold and to aggregate.
Other genes associated with ALS, but less well established, are Alsin (ALS2), Senataxin (SETX), and Vesicle-Associated Membrane Protein B (VAPB). These genes cause less typical forms of ALS. Mutations in the genes encoding Angiogenin (ANG), Dynactin-1 (DCTN1), Neurofilament heavy subunit (NEFH), or Peripherin (PRPH) appear to increase the risk of developing amyotrophic lateral sclerosis. Recently, mutations in the gene encoding TAR-DNA-Binding protein (TDP-43) have been found in fALS and sALS cases.
Amyotrophic lateral sclerosis (ALS, or Lou Gehrig’s disease) is a rapidly progressive motor neuron disease that attacks nerve cells (motor neurons) in the brain and spinal cord leading to paralysis.
In 2007, Tanz scientists developed the first antibody that specifically labels misfolded superoxide dismutase-1 (SOD1). Mutations in SOD1 are the only known cause of ALS.
The antibody has potential utility for use in biomarker studies, drug discovery and development of immunization strategies for the treatment of ALS caused by mutations in SOD1.
Tanz researchers were also the first to show that there is deregulated expression of alternatively spliced variants of the peripherin protein in ALS, and that these may play a role in the neurodegenerative process.